Mon. 8 Apr 2024, 8:20am ET
Benzinga
Biotech, News, Events, General
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified cancers
Third poster presentation to highlight the potential role of ecDNA-based resistance to chemotherapy